Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
KLK3
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "KLK3" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-P70606A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: KLK3; Kallikrein 3, (Prostate Specific Antigen), Isoform CRA_e; Prev. APS; Kallikrein 3, (Prostate Specific Antigen), Isoform CRA_d; PSA; Kallikrein 3, (Prostate Specific Antigen), Isoform CRA_f; Prostate Specific Antigen; Kallikrein 3, (Prostate Specific
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P70266
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: KLK3; Kallikrein 3, (Prostate Specific Antigen), Isoform CRA_e; Prev. APS; Kallikrein 3, (Prostate Specific Antigen), Isoform CRA_d; PSA; Kallikrein 3, (Prostate Specific Antigen), Isoform CRA_f; Prostate Specific Antigen; Kallikrein 3, (Prostate Specific
Species:
Human
Source:
HEK293
Cat. No.: HY-RS07381
Target:
Research Areas:
KLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for KLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-168201
CAS No.: 3105406-14-9
Research Areas:
MJP6412 is a p300 and CBP PROTAC degrader that potently degrades p300 and CBP in 22Rv1 cells with DC50 values of 1.6 nM and 1.2 nM, respectively. MJP6412 downregulates the expression of AR-FL, AR-V7 and c-MYC, as well as androgen receptor target genes (KLK3, FKBP5, TMPRSS2). MJP6412 completely abolishes p300/CBP-dependent histone acetylation (H3K27Ac and H2BNTAC) and induces G1 cell cycle arrest. MJP6412 inhibits cancer cell proliferation and tumor growth. MJP6412 can be used in prostate cancer-related research .
Cat. No.: HY-181971
Research Areas:
XY25028 is an orally active LRH-1 inhibitor with an IC50 of 0.30 μM. XY25028 inhibits the proliferation of androgen receptor (AR)-positive prostate cancer cells and suppresses the expression of AR target genes KLK2 and KLK3. XY25028 can be used in the research of castration-resistant prostate cancer .
Cat. No.: HY-181970
Research Areas:
XY25026 is an orally active LRH-1 inhibitor with an IC50 of 0.28 μM. XY25026 inhibits the proliferation of androgen receptor (AR)-positive prostate cancer cells, suppresses the expression of AR target genes KLK2 and KLK3, and inhibits tumor growth in xenograft models. XY25026 is applicable to the research of castration-resistant prostate cancer .
Cat. No.: HY-P700772
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: KLKB1; Fletcher Factor; Prev. KLK3; PKK; Kallikrein B, Plasma (Fletcher Factor) 1; PKKD; Plasma Prekallikrein; PPK; Plasma Kallikrein; Kallikrein B1; Kininogenin
Species:
Cynomolgus
Source:
HEK293
Cat. No.: HY-P77973A
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: KLKB1; Fletcher Factor; Prev. KLK3; PKK; Kallikrein B, Plasma (Fletcher Factor) 1; PKKD; Plasma Prekallikrein; PPK; Plasma Kallikrein; Kallikrein B1; Kininogenin
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P70249A
Purity: ≥ 95% as determined by reducing SDS-PAGE or Bis-Tris PAGE.
Synonyms: KLKB1; Fletcher Factor; Prev. KLK3; PKK; Kallikrein B, Plasma (Fletcher Factor) 1; PKKD; Plasma Prekallikrein; PPK; Plasma Kallikrein; Kallikrein B1; Kininogenin
Species:
Human
Source:
HEK293
Cat. No.: HY-RS24126
Target:
Research Areas:
Klkb1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Klkb1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-184896
CAS No.: 3032314-99-8
Target:
Molecular Glues Eukaryotic Release Factor (eRF) c-Myc Androgen Receptor Kallikrein Ser/Thr Protease E1/E2/E3 Enzyme
Research Areas:
XYD113 is an orally active, selective GSPT1 Molecular glue degrader. XYD113 promotes the formation of the CRBN-GSPT1 ternary complex and mediates GSPT1 degradation in a CRBN-dependent manner via the ubiquitin-proteasome system. XYD113 downregulates genes associated with the occurrence and progression of prostate cancer (c-Myc, AR, AR-V7, KLK3, KLK2, TMPRSS2). XYD113 exhibits anticancer activity against prostate cancer. XYD113 can be used in the research of prostate cancer .
Cat. No.: HY-183667
CAS No.: 1332390-06-3
Target:
Research Areas:
JNJ-pan-AR is an orally active androgen receptor (AR) inhibitor with an IC50 of 19 nM and a Ki of 8.4 nM against human wild-type AR. JNJ-pan-AR abolishes androgen-induced KLK2 and KLK3 mRNA expression and reduces androgen-dependent colony formation in prostate cancer cells. JNJ-pan-AR blocks AR nuclear translocation, inhibits PSA protein expression, and represses the growth of AR-dependent tumor cells and ARF877L-driven tumor xenografts. JNJ-pan-AR blocks transactivation and signaling of wild-type AR and various mutant AR variants. JNJ-pan-AR is applicable for research on castration-resistant prostate cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
